AURORA CANNABIS IN COM NPV (OTCMKTS:ACBFF) Launches Unique Products on Cannabis Holiday


AURORA CANNABIS IN COM NPV (OTCMKTS:ACBFF) has taken advantage of the increased cannabis sector visibility that the 4/20 holiday provides by announcing a new product line. We’ve been tracking this company here on Street Register for quite some time, and the new announcement is definitely exciting for those of us who continuously follow the ACBFF story.

To promote new product on the most high-profile day of the year in your industry is just good sense. We’re not surprised at all to see the company choose 4/20 as the launch date.

AURORA CANNABIS IN COM NPV (OTCMKTS:ACBFF) has now commenced sales of a new line of ingestible cannabis oils called Aurora Drops. The Company’s newest offerings include three distinct product types all priced equally at a standard flat rate of $115 per bottle, or $80 per bottle for clients approved for Aurora’s compassionate pricing program:

  1. THC Drops (Sativa) – a high potency THC oil extracted from Cannabis Sativa flowers
  2. THC Drops (Indica) – a high potency THC oil extracted from Cannabis Indica flowers
  3. CBD Drops – a high potency oil extracted from Aurora’s flagship CBD strain Temple (Cannatonic)

The Company’s ingestible cannabis oils come in 30 ml glass bottles with a child resistant certified cap and dropper to allow for the easy and accurate dosing of small amounts of the high potency fluids, and are produced using CGMP compliant supercritical CO2 extraction technology, as well as using an MCT carrier oil sourced from coconut oil.

As with all of Aurora’s cannabis products, the test results from the independent third-party lab for each batch of ingestible oil are publicly available. Test results can be accessed online at, or through the Aurora Mobile app for iOS and Android that displays inventory tracking and restocking events, and sends push notifications for new product releases.

“The launch of our first ingestible oil products represents a major milestone, which promises to add significantly to Aurora’s top and bottom line results,” said Neil Belot, Chief Global Business Development Officer.  “We have produced a sizeable inventory of Aurora Drops for our domestic medical client base, and will be continuing to ramp up production in order to address the strong demand we anticipate for high-quality, high-margin derivative products, manufactured under the rigorous Aurora Standards regarding processes, testing, and transparency.”

The Company recently signed a Memorandum of Understanding with Radient Technologies Inc. (“RTI”) with regards to the joint development and commercialization in Canada of superior and standardized cannabinoid extracts produced using RTI’s high-throughput, terpene-preserving, proprietary extraction technology.

“The strategic partnership with RTI has the potential to be a game changer in this high-margin, high-growth segment of the cannabis market, “said Terry Booth, CEO. “If the technology works as we anticipate, Aurora will be able to produce high volumes of terpene-rich cannabis derivatives at lower costs and much shorter harvest-to-market times than any company using current industry benchmark technologies. This would give us an even stronger competitive advantage in what may well become the dominant market segment. The launch of sales is the first step in establishing our brand in the derivatives market, and we are very pleased that we are able to expand our offering to a customer base looking for alternative methods to consume cannabis.” (Source: Canada Newswire)

ACBFF has continued to be one of the hottest marijuana related stocks from North of the Border- one of our favorites to cover- and Canada is on the cusp of taking measures to legalize cannabis nationwide. Stay locked to Street Register for updates, and we’ll deliver important developments on ACBFF as they unfold. In the meantime, if you’ve yet to sign up for our 100% free newsletter, do so now! Just enter your active email address into the box below and submit!

Disclosure: No one at Street Register has been compensated in any way for the publishing of this article, nor do we hold any position in ACBFF stock, short or long.